Skip to main content

Advertisement

SpringerLink
Log in

Downregulation of SERINC5 expression in buffy coats of HIV-1-infected patients with detectable or undetectable viral load

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Among the host restriction factors against HIV, SERINC5 has been described in vitro, but the mRNA level of SERINC5 in vivo has been little studied. We compare SERINC5 expression in subjects with HIV-1 (highly active antiretroviral treatment (HAART) and HAART-naïve) with and without suppression of viral load. A cross-sectional study was performed with 107 individuals distributed as follows: 24 with HAART-naïve and detectable viral load (> 50 copies/mL), 13 with HAART and detectable viral load (> 50 copies/mL), 50 with HAART and undetectable viral load (≤ 50 copies/mL), and 20 without HIV-1. SERINC5 expression in buffy coats was determined using RT-qPCR. The viral load was determined using real-time PCR and the amount of CD4 + and CD8 + T-lymphocytes was measured using flow cytometry. The data were normalized with the Shapiro–Wilk test and the Kruskal–Wallis test was subsequently performed. The relative expression was compared with a T-test and the remaining data with the Mann–Whitney U-test. ANCOVA multiple linear regression analysis was performed between characteristics of patients with SERINC5 expression. The mean and SD of the SERINC5 expression in the three groups with HIV-1 was 0.9 ± 0.2 and without HIV-1 was 1.7 ± 0.14 (P < 0.001). Multiple linear regression did not show the participation of CD4 +, CD8 + , viral load, infection time, or treatment time. No differences in the SERINC5 expression were found among the studied groups of patients with HIV-1. When comparing the groups with and without HIV-1 infection, SERINC5 was downregulation in the HIV-1 groups.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Firrito C, Bertelli C, Vanzo T, Chande A, Pizzato M (2018) SERINC5 as a new restriction factor for human immunodeficiency virus and murine leukemia virus. Annu Rev Virol 5:323–340. https://doi.org/10.1146/annurev-virology-092917-043308

    Article  CAS  PubMed  Google Scholar 

  2. Zutz A, Schölz C, Schneider S, Pierini V, Münchhoff M, Sutter K et al (2020) SERINC5 is an unconventional HIV restriction factor that is upregulated during myeloid cell differentiation. J Innate Immun 14:1–11. https://doi.org/10.1159/000504888

    Article  CAS  Google Scholar 

  3. Trautz B, Wiedemann H, Lüchtenborg C, Pierini V, Kranich J, Glass B et al (2017) The host-cell restriction factor SERINC5 restricts HIV-1 infectivity without altering the lipid composition and organization of viral particles. J Biol Chem 292:13702–13713. https://doi.org/10.1074/jbc.M117.797332

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Passos V, Zillinger T, Casartelli N, Wachs AS, Xu S, Malassa A et al (2019) Characterization of endogenous SERINC5 protein as anti-HIV-1 factor. J Virol 93(24):e01221-19. https://doi.org/10.1128/JVI.01221-19

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, Goh SL et al (2015) HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526:212–217. https://doi.org/10.1128/JVI.00196-18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Usami Y, Wu Y, Göttlinger HG (2015) SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526:218–223. https://doi.org/10.1038/nature15400

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Featherstone A, Aiken C (2020) SERINC5 inhibits HIV-1 infectivity by altering the conformation of gp120 on HIV-1 particles. J Virol 94:e00594-20. https://doi.org/10.1128/JVI.00594-20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Sood C, Marin M, Chande A, Pizzato M, Melikyan GB (2017) SERINC5 protein inhibits HIV-1 fusion pore formation by promoting functional inactivation of envelope glycoproteins. J Biol Chem 292:6014–6026. https://doi.org/10.1074/jbc.M117.777714

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Gonzalez-Enriquez GV, Escoto-Delgadillo M, Vazquez-Valls E, Torres-Mendoza BM (2017) SERINC as a restriction factor to inhibit viral infectivity and the interaction with HIV. J Immunol Res. https://doi.org/10.1155/2017/1548905

    Article  PubMed  PubMed Central  Google Scholar 

  10. Lai RP, Yan J, Heeney J, McClure MO, Göttlinger H, Luban J et al (2011) Nef decreases HIV-1 sensitivity to neutralizing antibodies that target the membrane-proximal external region of TMgp41. PLoS Pathog 7:e1002442. https://doi.org/10.1371/journal.ppat.1002442

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Bolduan S, Koppensteiner H, Businger R, Rebensburg S, Kunze C, Brack-Werner R et al (2017) T cells with low CD2 levels express reduced restriction factors and are preferentially infected in therapy naïve chronic HIV-1 patients. J Int AIDS Soc 20:21865. https://doi.org/10.7448/IAS.20.1.21865

    Article  PubMed  PubMed Central  Google Scholar 

  12. Timilsina U, Umthong S, Lynch B, Stablewski A, Stavrou S (2020) SERINC5 potently restricts retrovirus infection in vivo. mBio 11:e00588-20. https://doi.org/10.1128/mBio.00588-20

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Stoneham CA, Ramirez PW, Singh R, Suarez M, Debray A, Lim C et al (2020) A conserved acidic cluster motif in SERINC5 confers partial resistance to antagonism by HIV-1 Nef. J Virol 94:e01554-e1619. https://doi.org/10.1128/JVI.01554-19

    Article  PubMed  PubMed Central  Google Scholar 

  14. Bachtel ND, Beckerle GA, Mota TM, Rougvie MM, Raposo RAS, Jones RB et al (2019) Short communication: expression of host restriction factors by memory CD4+ T cells differs between healthy donors and HIV-1-infected individuals with effective antiretroviral therapy. AIDS Res Hum Retroviruses 35:108–111. https://doi.org/10.1089/AID.2018.0162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Hileman CO, Funderburg NT (2017) Inflammation, immune activation, and antiretroviral therapy in HIV. Curr HIV/AIDS Rep 14:93–100. https://doi.org/10.1007/s11904-017-0356-x

    Article  PubMed  PubMed Central  Google Scholar 

  16. Strebel K (2013) HIV accessory proteins versus host restriction factors. Curr Opin Virol 3:692–699. https://doi.org/10.1016/j.coviro.2013.08.004

    Article  CAS  PubMed  Google Scholar 

  17. Leng J, Ho HP, Buzon MJ, Pereyra F, Walker BD, Yu XG et al (2014) A cell-intrinsic inhibitor of HIV-1 reverse transcription in CD4(+) T cells from elite controllers. Cell Host Microbe 15:717–728. https://doi.org/10.1016/j.chom.2014.05.011

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Kelesidis T, Tran TT, Stein JH, Brown TT, Moser C, Ribaudo HJ et al (2015) Changes in inflammation and immune activation with atazanavir-, raltegravir-, darunavir-based initial antiviral therapy: ACTG 5260s. Clin Infect Dis 61:651–660. https://doi.org/10.1093/cid/civ327

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Clayton KL, Collins DR, Lengieza J, Ghebremichael M, Dotiwala F, Lieberman J et al (2018) Resistance of HIV-infected macrophages to CD8+ T lymphocyte-mediated killing drives activation of the immune system. Nat Immunol 19:475–486. https://doi.org/10.1038/s41590-018-0085-3

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nodder SB, Gummuluru S (2019) Illuminating the role of Vpr in HIV infection of myeloid cells. Front Immunol 10:1606. https://doi.org/10.3389/fimmu.2019.01606

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Pye VE, Rosa A, Bertelli C, Struwe WB, Maslen SL, Corey R et al (2020) A bipartite structural organization defines the SERINC family of HIV-1 restriction factors. Nat Struct Mol Biol 27:78–83. https://doi.org/10.1038/s41594-019-0357-0

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ghimire D, Rai M, Gaur R (2018) Novel host restriction factors implicated in HIV-1 replication. J Gen Virol 99:435–446. https://doi.org/10.1099/jgv.0.001026

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank Izchel Figarola-Centurion for their assistance in translating the manuscript.

Funding

Elsie Guadalupe Hernández-López is Ph.D. student in Pharmacology and received fellowships from Consejo Nacional de Ciencia y Tecnología with Number 761820.

Author information

Author notes

  1. Elsie Guadalupe Hernández-López and Gracia Viviana González-Enríquez equally contributed to this work.

Authors and Affiliations

  1. Doctorado en Farmacología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México

    Elsie Guadalupe Hernández-López & Ana Rosa Rincón-Sánchez

  2. Departamento de Disciplinas Filosófico, Metodológicas e Instrumentales, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México

    Gracia Viviana González-Enríquez, Blanca Miriam Torres-Mendoza & Jhonathan Cárdenas-Bedoya

  3. Laboratorio de Inmunodeficiencias y Retrovirus Humanos, Centro de Investigación Biomédica de Occidente, Centro Médico Nacional de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México

    Blanca Miriam Torres-Mendoza, Jhonathan Cárdenas-Bedoya, Martha Escoto-Delgadillo & David Alejandro Carbajal-Uribe

  4. Centro Universitario de Ciencias Biológicas y Agropecuarias, Universidad de Guadalajara, Zapopan, Jalisco, México

    Martha Escoto-Delgadillo

  5. Dirección de Generación de Recursos Profesionales, Investigación Y Desarrollo de la Secretaría de Salud, Jalisco, Guadalajara, Jalisco, México

    Eduardo Vázquez-Valls

  6. Hospital Regional 110, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México

    Alma Minerva Pérez-Ríos

Authors
  1. Elsie Guadalupe Hernández-López
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gracia Viviana González-Enríquez
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Blanca Miriam Torres-Mendoza
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jhonathan Cárdenas-Bedoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Martha Escoto-Delgadillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Eduardo Vázquez-Valls
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Alma Minerva Pérez-Ríos
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. David Alejandro Carbajal-Uribe
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ana Rosa Rincón-Sánchez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Study conception and design [BMTM, GVGE]; Material preparation and data collection were performed by [EGHL, JCB and DACU]; Participant capture and medical history record: [AMRP, DACU]; analysis expression and data interpretation: [GVGE, EGHL, JCB]; Funding acquisition: [BMTM]; Resources: [EVV]; Supervision: [MED]; Writing—original draft preparation: [EGHL, GVGE]; Writing—review and editing: [BMTM, EVV, MED, ARRS], and all authors commented and contributed to the conception of the manuscript, they revised and approved the final manuscript.

Corresponding author

Correspondence to Blanca Miriam Torres-Mendoza.

Ethics declarations

Conflict of interest

The authors declare that there are no conflicts of interest regarding the publication of this paper.

Ethical approval

All procedures performed were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. Written informed consent was obtained from all participants.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 20 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hernández-López, E.G., González-Enríquez, G.V., Torres-Mendoza, B.M. et al. Downregulation of SERINC5 expression in buffy coats of HIV-1-infected patients with detectable or undetectable viral load. Mol Biol Rep 48, 4247–4252 (2021). https://doi.org/10.1007/s11033-021-06438-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-021-06438-2

Keywords

Search

Navigation